首页 > 市场调查报告书 > 製药

疼痛

市场调查报告书

商品编码

1747115

日本疼痛管理药物市场规模、份额、趋势及预测（按药品类别、适应症、配销通路和地区划分），2025 年至 2033 年

Japan Pain Management Drugs Market Size, Share, Trends and Forecast by Drug Class, Indication, Distribution Channel, and Region, 2025-2033

出版日期: 2025年06月02日 | 出版商:

IMARC | 英文 116 Pages | 商品交期: 5-7个工作天内

价格

简介目录

2024年，日本疼痛管理药物市场规模达42.2267亿美元。展望未来， IMARC Group预计到2033年，市场规模将达到52.0448亿美元，2025-2033年期间的复合年增长率（CAGR）为2.35%。受人口老化、药物输送创新以及非鸦片类药物治疗需求成长的推动，日本市场正经历显着成长。此外，严格的监管和医疗改革持续影响全国市场扩张和治疗的进步。

日本疼痛管理药物市场趋势：

老年人口不断增加

日本人口老化是疼痛管理药物产业持续需求的重要驱动力。老年人口的不断增长直接影响着日本疼痛管理药物市场的成长，因为与年龄相关的健康问题，例如骨关节炎、慢性背痛和神经性疾病变得越来越普遍。据报道，日本老年人口达到创纪录的3,625万，占总人口的29.3%。 65岁以上女性占2053万，男性占1572万人。此外，914万老年人就业，反映出随着人口连续13年下降，人口结构面临的挑战仍在持续。日本的预期寿命位居全球前列，很大一部分人口需要长期持续的疼痛缓解疗法。这些疗法通常包括非类固醇抗发炎药、抗忧郁药物以及针对老年人的专门治疗，而老年人也更容易受到药物敏感性和副作用的影响。医疗保健提供者正在透过优先考虑更安全、更低剂量的製剂和监测方案来适应这种情况。此外，与年龄相关的手术（例如关节置换术）的增多，也刺激了术后止痛药的需求。随着日本人口结构转变的加深，此趋势将持续提升日本疼痛管理药物在各类治疗领域的市场占有率。

药物输送和配方的创新

日本製药公司正积极创新给药方式，以改善治疗效果并提升患者舒适度。随着对慢性疼痛和老年护理的日益关注，各公司正转向透皮贴片、缓释片以及外用凝胶或喷雾等先进技术。这些替代方案能够实现更精准的给药、持续的疼痛缓解，并减少胃肠道或全身副作用，这对老年人和长期用药者尤其重要。製剂创新还包括开发复方药物和新型化合物，以更有效地缓解疼痛并降低依赖风险。例如，2024年11月，卫材株式会社在日本推出了注射用Rozebalamin(R) 25毫克（甲钴胺），用于减缓肌萎缩侧索硬化症(ALS)患者的功能障碍并缓解疼痛。该药物于9月获得批准，此前已进行130名患者的III期临床试验。这些进步不仅提高了患者的依从性，也扩展了跨治疗类别的产品供应。随着监管机构支持更安全的替代品，医疗保健专业人员采用更新的交付方式，创新预计将在未来几年塑造日本疼痛管理药物市场前景方面发挥关键作用。

日本疼痛管理药物市场区隔：

药物类别洞察：

非类固醇抗发炎药
麻醉药
抗惊厥药
抗偏头痛药物
抗忧郁药
阿片类药物
其他的

指示见解：

肌肉骨骼疼痛
手术和创伤疼痛
癌症痛
神经性疼痛
偏头痛
产科疼痛
纤维肌痛
烧伤痛
牙齿/脸部疼痛
儿童疼痛
其他的

配销通路洞察：

医院药房
零售药局
网路药局

竞争格局：

市场研究报告也对竞争格局进行了全面的分析。报告涵盖了市场结构、关键参与者定位、最佳制胜策略、竞争仪錶板和公司评估象限等竞争分析。此外，报告还提供了所有主要公司的详细资料。

本报告回答的关键问题：

日本疼痛管理药物市场迄今表现如何？未来几年将如何表现？
根据药品类别，日本疼痛管理药物市场是如何分類的？
日本疼痛管理药物市场根据适应症的划分是怎样的？
根据配销通路，日本疼痛管理药物市场是如何分類的？
日本疼痛管理药物市场按地区分類的分布如何？
日本疼痛管理药物市场的价值链分为哪些阶段？
日本疼痛管理药物市场的主要驱动因素和挑战是什么？
日本疼痛管理药物市场的结构是怎么样的？主要参与者是谁？
日本疼痛管理药物市场的竞争程度如何？

本报告回答的关键问题：

日本疼痛管理药物市场迄今表现如何？未来几年将如何表现？
根据药品类别，日本疼痛管理药物市场是如何分類的？
日本疼痛管理药物市场根据适应症的划分是怎样的？
根据配销通路，日本疼痛管理药物市场是如何分類的？
日本疼痛管理药物市场按地区分類的分布如何？
日本疼痛管理药物市场的价值链分为哪些阶段？
日本疼痛管理药物市场的主要驱动因素和挑战是什么？
日本疼痛管理药物市场的结构是怎么样的？主要参与者是谁？
日本疼痛管理药物市场的竞争程度如何？

The Japan pain management drugs market size reached USD 4,222.67 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 5,204.48 Million by 2033, exhibiting a growth rate (CAGR) of 2.35% during 2025-2033. The market is experiencing significant growth, driven by an aging population, innovation in drug delivery, and rising demand for non-opioid treatments. Moreover, strict regulations and healthcare reforms continue to shape market expansion and therapeutic advancements nationwide.

Japan Pain Management Drugs Market Trends:

Rising Geriatric Population

Japan's aging population is a significant driver of sustained demand in the pain management drugs industry. The increasing number of elderly individuals is directly influencing Japan pain management drugs market growth, as age-related health issues such as osteoarthritis, chronic back pain, and neuropathic conditions become more prevalent. According to the reports, Japan's elderly population reached a record 36.25 million, making up 29.3% of the total population. Women aged 65 or older account for 20.53 million, while men total 15.72 million. Additionally, 9.14 million elderly are employed, reflecting ongoing demographic challenges as the population declines for the 13th consecutive year. With life expectancy among the highest globally, a large segment of the population requires long-term, consistent pain relief therapies. These often include a combination of NSAIDs, antidepressants, and specialized treatments tailored to older adults, who are also more vulnerable to drug sensitivity and side effects. Healthcare providers are adapting by prioritizing safer, lower-dose formulations and monitoring protocols. Additionally, the rising rate of age-related surgeries, such as joint replacements, is fueling demand for post-operative pain medications. As Japan's demographic shift deepens, this trend will continue to increase the Japan pain management drugs market share across therapeutic categories.

Innovation in Drug Delivery and Formulation

Japanese pharmaceutical companies are actively innovating drug delivery methods to improve treatment outcomes and enhance patient comfort. With a growing focus on chronic pain and elderly care, firms are shifting toward advanced options such as transdermal patches, extended-release tablets, and topical gels or sprays. These alternatives allow for more precise dosing, sustained pain relief, and reduced gastrointestinal or systemic side effects, which are particularly important for older adults and long-term users. Innovation in formulation also includes development of combination drugs and novel compounds that target pain more efficiently while reducing dependency risks. For instance, in November 2024, Eisai Co., Ltd. launched Rozebalamin(R) for Injection 25 mg (mecobalamin) in Japan, to slow functional impairment and address pain in amyotrophic lateral sclerosis (ALS) patients. Approved in September, it follows a Phase III trial with 130 patients. These advancements are not only improving adherence but also expanding product offerings across therapeutic categories. As regulatory bodies support safer alternatives and healthcare professionals adopt newer delivery formats, innovation is expected to play a key role in shaping the Japan pain management drugs market outlook in the coming years.

Japan Pain Management Drugs Market Segmentation:

Drug Class Insights:

NSAIDs
Anesthetics
Anticonvulsants
Antimigraine Agents
Antidepressants
Opioids
Others

Indication Insights:

Musculoskeletal Pain
Surgical and Trauma Pain
Cancer Pain
Neuropathic Pain
Migraine Pain
Obstetrical Pain
Fibromyalgia Pain
Burn Pain
Dental/Facial Pain
Pediatric Pain
Others

Distribution Channel Insights:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

How has the Japan pain management drugs market performed so far and how will it perform in the coming years?
What is the breakup of the Japan pain management drugs market on the basis of drug class?
What is the breakup of the Japan pain management drugs market on the basis of indication?
What is the breakup of the Japan pain management drugs market on the basis of distribution channel?
What is the breakup of the Japan pain management drugs market on the basis of region?
What are the various stages in the value chain of the Japan pain management drugs market?
What are the key driving factors and challenges in the Japan pain management drugs market?
What is the structure of the Japan pain management drugs market and who are the key players?
What is the degree of competition in the Japan pain management drugs market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Japan Pain Management Drugs Market - Introduction

4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence

5 Japan Pain Management Drugs Market Landscape

5.1 Historical and Current Market Trends (2019-2024)
5.2 Market Forecast (2025-2033)

6 Japan Pain Management Drugs Market - Breakup by Drug Class

6.1 NSAIDs
- 6.1.1 Overview
- 6.1.2 Historical and Current Market Trends (2019-2024)
- 6.1.3 Market Forecast (2025-2033)
6.2 Anesthetics
- 6.2.1 Overview
- 6.2.2 Historical and Current Market Trends (2019-2024)
- 6.2.3 Market Forecast (2025-2033)
6.3 Anticonvulsants
- 6.3.1 Overview
- 6.3.2 Historical and Current Market Trends (2019-2024)
- 6.3.3 Market Forecast (2025-2033)
6.4 Antimigraine Agents
- 6.4.1 Overview
- 6.4.2 Historical and Current Market Trends (2019-2024)
- 6.4.3 Market Forecast (2025-2033)
6.5 Antidepressants
- 6.5.1 Overview
- 6.5.2 Historical and Current Market Trends (2019-2024)
- 6.5.3 Market Forecast (2025-2033)
6.6 Opioids
- 6.6.1 Overview
- 6.6.2 Historical and Current Market Trends (2019-2024)
- 6.6.3 Market Forecast (2025-2033)
6.7 Others
- 6.7.1 Historical and Current Market Trends (2019-2024)
- 6.7.2 Market Forecast (2025-2033)

7 Japan Pain Management Drugs Market - Breakup by Indication

7.1 Musculoskeletal Pain
- 7.1.1 Overview
- 7.1.2 Historical and Current Market Trends (2019-2024)
- 7.1.3 Market Forecast (2025-2033)
7.2 Surgical and Trauma Pain
- 7.2.1 Overview
- 7.2.2 Historical and Current Market Trends (2019-2024)
- 7.2.3 Market Forecast (2025-2033)
7.3 Cancer Pain
- 7.3.1 Overview
- 7.3.2 Historical and Current Market Trends (2019-2024)
- 7.3.3 Market Forecast (2025-2033)
7.4 Neuropathic Pain
- 7.4.1 Overview
- 7.4.2 Historical and Current Market Trends (2019-2024)
- 7.4.3 Market Forecast (2025-2033)
7.5 Migraine Pain
- 7.5.1 Overview
- 7.5.2 Historical and Current Market Trends (2019-2024)
- 7.5.3 Market Forecast (2025-2033)
7.6 Obstetrical Pain
- 7.6.1 Overview
- 7.6.2 Historical and Current Market Trends (2019-2024)
- 7.6.3 Market Forecast (2025-2033)
7.7 Fibromyalgia Pain
- 7.7.1 Overview
- 7.7.2 Historical and Current Market Trends (2019-2024)
- 7.7.3 Market Forecast (2025-2033)
7.8 Burn Pain
- 7.8.1 Overview
- 7.8.2 Historical and Current Market Trends (2019-2024)
- 7.8.3 Market Forecast (2025-2033)
7.9 Dental/Facial Pain
- 7.9.1 Overview
- 7.9.2 Historical and Current Market Trends (2019-2024)
- 7.9.3 Market Forecast (2025-2033)
7.10 Pediatric Pain
- 7.10.1 Overview
- 7.10.2 Historical and Current Market Trends (2019-2024)
- 7.10.3 Market Forecast (2025-2033)
7.11 Others
- 7.11.1 Historical and Current Market Trends (2019-2024)
- 7.11.2 Market Forecast (2025-2033)

8 Japan Pain Management Drugs Market - Breakup by Distribution Channel

8.1 Hospital Pharmacies
- 8.1.1 Overview
- 8.1.2 Historical and Current Market Trends (2019-2024)
- 8.1.3 Market Forecast (2025-2033)
8.2 Retail Pharmacies
- 8.2.1 Overview
- 8.2.2 Historical and Current Market Trends (2019-2024)
- 8.2.3 Market Forecast (2025-2033)
8.3 Online Pharmacies
- 8.3.1 Overview
- 8.3.2 Historical and Current Market Trends (2019-2024)
- 8.3.3 Market Forecast (2025-2033)

9 Pediatric Pain

7.9.1 Overview
7.9.2 Historical and Current Market Trends (2019-2024)
7.9.3 Market Forecast (2025-2033)

7.10 Others
- 7.10.1 Historical and Current Market Trends (2019-2024)
- 7.10.2 Market Forecast (2025-2033)

8 Japan Pain Management Drugs Market - Breakup by Distribution Channel

8.1 Hospital Pharmacies
- 8.1.1 Overview
- 8.1.2 Historical and Current Market Trends (2019-2024)
- 8.1.3 Market Forecast (2025-2033)
8.2 Retail Pharmacies
- 8.2.1 Overview
- 8.2.2 Historical and Current Market Trends (2019-2024)
- 8.2.3 Market Forecast (2025-2033)
8.3 Online Pharmacies
- 8.3.1 Overview
- 8.3.2 Historical and Current Market Trends (2019-2024)
- 8.3.3 Market Forecast (2025-2033)

9 Japan Pain Management Drugs Market - Competitive Landscape

9.1 Overview
9.2 Market Structure
9.3 Market Player Positioning
9.4 Top Winning Strategies
9.5 Competitive Dashboard
9.6 Company Evaluation Quadrant

10 Profiles of Key Players

10.1 Company A
- 10.1.1 Business Overview
- 10.1.2 Products Offered
- 10.1.3 Business Strategies
- 10.1.4 SWOT Analysis
- 10.1.5 Major News and Events
10.2 Company B
- 10.2.1 Business Overview
- 10.2.2 Products Offered
- 10.2.3 Business Strategies
- 10.2.4 SWOT Analysis
- 10.2.5 Major News and Events
10.3 Company C
- 10.3.1 Business Overview
- 10.3.2 Products Offered
- 10.3.3 Business Strategies
- 10.3.4 SWOT Analysis
- 10.3.5 Major News and Events
10.4 Company D
- 10.4.1 Business Overview
- 10.4.2 Products Offered
- 10.4.3 Business Strategies
- 10.4.4 SWOT Analysis
- 10.4.5 Major News and Events
10.5 Company E
- 10.5.1 Business Overview
- 10.5.2 Products Offered
- 10.5.3 Business Strategies
- 10.5.4 SWOT Analysis
- 10.5.5 Major News and Events

11 Japan Pain Management Drugs Market - Industry Analysis

11.1 Drivers, Restraints, and Opportunities
- 11.1.1 Overview
- 11.1.2 Drivers
- 11.1.3 Restraints
- 11.1.4 Opportunities
11.2 Porters Five Forces Analysis
- 11.2.1 Overview
- 11.2.2 Bargaining Power of Buyers
- 11.2.3 Bargaining Power of Suppliers
- 11.2.4 Degree of Competition
- 11.2.5 Threat of New Entrants
- 11.2.6 Threat of Substitutes
11.3 Value Chain Analysis